metformin has been researched along with carvedilol in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, EC; Chien, HC; Giacomini, KM; Huang, Y; Khuri, N; Liang, X; Sali, A; Stecula, A; Yee, SW | 1 |
| Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT | 1 |
| Bachmakov, I; Endress, B; Fromm, MF; Glaeser, H; König, J; Mörl, F | 1 |
| Harper, JN; Wright, SH | 1 |
| Antenore, A; Bagnoli, P; Dicembrini, I; Filippi, L; Mannucci, E; Marchionni, N; Monami, M; Rotella, CM; Sgrilli, F; Ungar, A | 1 |
| Akabuogu, EU; Phyu, SM; Smith, TA | 1 |
| Coelho, EB; Lanchote, VL; Nardotto, GHB; Paiva, CE | 1 |
| Coelho, EB; Della Pasqua, O; Lanchote, VL; Nardotto, GHB | 1 |
| Bae, HJ; Guo, D; Li, Q; Obianom, O; Polli, JE; Shu, Y; Su, T; Yang, H; Zeng, S | 1 |
| Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z | 1 |
2 review(s) available for metformin and carvedilol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabetes Mellitus; Ethanolamines; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Myocardial Ischemia; Nebivolol; Neoplasms; Propanolamines; Risk | 2013 |
3 trial(s) available for metformin and carvedilol
| Article | Year |
|---|---|
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Insulin Resistance; Male; Metformin; Metoprolol; Middle Aged; Propanolamines; Thiazolidinediones; Treatment Outcome | 2007 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabetes Mellitus; Ethanolamines; Female; Humans; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Myocardial Ischemia; Nebivolol; Neoplasms; Propanolamines; Risk | 2013 |
Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Area Under Curve; Carbazoles; Carvedilol; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Hand Strength; Heart Rate; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Propanolamines; Stereoisomerism | 2017 |
14 other study(ies) available for metformin and carvedilol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
Topics: Drug Discovery; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Organic Cation Transporter 1; Small Molecule Libraries | 2017 |
Interaction of beta-blockers with the renal uptake transporter OCT2.
Topics: Adrenergic beta-Antagonists; Biological Transport; Bisoprolol; Carbazoles; Carvedilol; Cell Line; Humans; Kidney; Metformin; Metoprolol; Organic Cation Transport Proteins; Organic Cation Transporter 2; Propanolamines; Propranolol | 2009 |
Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.
Topics: 1-Methyl-4-phenylpyridinium; Androstenes; Animals; Benzhydryl Compounds; Carbazoles; Carvedilol; CHO Cells; Cimetidine; Cricetinae; Cricetulus; Humans; Inhibitory Concentration 50; Kinetics; Ligands; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 2; Piperidines; Propanolamines; Tetraethylammonium | 2013 |
Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cardiomyopathies; Cardiotonic Agents; Cardiovascular Agents; Carvedilol; Cell Line, Tumor; Cell Survival; Dexrazoxane; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Enalapril; Female; Fluorodeoxyglucose F18; Humans; Metformin; Propanolamines; Radionuclide Imaging; Radiopharmaceuticals; Receptor, ErbB-2; Trastuzumab | 2016 |
Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Topics: Adrenergic beta-Antagonists; Adult; Blood Glucose; Carbazoles; Carvedilol; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2D6; Diabetes Mellitus, Type 2; Female; Glyburide; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Propanolamines; Stereoisomerism | 2017 |
Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
Topics: Animals; Antineoplastic Agents; Carvedilol; Cell Survival; Cisplatin; HEK293 Cells; Humans; Kidney; Kidney Diseases; Male; Metformin; Mice, Inbred C57BL; Organic Cation Transport Proteins; Protective Agents | 2018 |
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Cirrhosis; Medicare; Metformin; Paracentesis; Rifaximin; Risk Factors; United States | 2022 |